<DOC>
	<DOCNO>NCT02940561</DOCNO>
	<brief_summary>To characterize pharmacokinetic profile Test product - Methotrexate Tablets USP , 2.5 mg Amneal Pharmaceuticals , compare corresponding Reference product - Methotrexate Tablets USP 2.5 mg manufacture DAVA Pharmaceuticals , Inc. patient mild severe psoriasis rheumatoid arthritis , already establish regimens 2.5 mg every 12 hour three dos per week fasting condition , assess bioequivalence .</brief_summary>
	<brief_title>BE Study Patients - Methotrexate Tablets</brief_title>
	<detailed_description>Patients continue establish dose 2.5 mg tablet 12 hour interval 3 dos give course weekly . This dose regimen keep constant throughout study period . On day 0 period , patient hospitalized/ house clinical facility/hospital , patient administer IP dose day 1 supervision train study staff . In supervised dosing , patient administer oral dose Methotrexate Tablet 2.5 mg ( Test Reference product per randomization schedule ) approximately 240 mL water ambient temperature sit position . Mouth check do investigator/ designee follow IP administration verify dose compliance . The patient advise take two subsequent dos locally approve drug every 12 hour interval administration study drug day 1 . Compliance subsequent two dos locally approve Methotrexate tablet 2.5 mg ensured period . The dose give 12 hour IP administration ( Second dose ) administer inside clinical facility collection 12 hour post-dose PK sample supervision train study personnel . The next dose ( third dose ) provide patient instruction take . Telephonic follow-up make next day third dose . The documented patient dose log . In period I , patient house day 0 least 12 hour prior IP dose schedule day 1 remain clinical facility till last PK sample day 1 . Patient check day 1 last PK blood sample collection follow administration second dose locally approve Methotrexate 2.5 mg tablet . The third dose locally approve Methotrexate 2.5 mg tablet take patient approximately 12 hour second dose . The procedure follow period II . There period least 7 day first dose ( IP administration ) study period . The patient stay hospitalized period 2 day 1 night study period convenience close safety monitoring .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients mild severe psoriasis rheumatoid arthritis , already establish regimens 2.5 mg every 12 hour ( 7.5 mg per week three divide dos ) Confirmed diagnosis psoriasis clinical examination dermatologic consultation . confirm diagnosis mild severe rheumatoidarthritis base least 1 follow : i. Documented history positive rheumatoid factor ii . Current presence rheumatoid factor iii . Radiographic erosion within 12 month prior enrollment iv . Presence serum anticyclic citrullinated peptide antibody ( antiCCP ) . Women childbearing potential ( include girl enter puberty woman uterus ovary complete menopause wherein menopause permanent end menstruation fertility . Females 12 consecutive month spontaneous amenorrhea ( induced medical condition medical therapy ) bilateral absence ovary ( surgical congenital ) complete menopause must negative serum pregnancy test screen negative urine pregnancy test check housing , must agree use adequate method contraception . Patient 's screen laboratory assessment ( complete blood count [ CBC ] blood chemistry ) clinically nonsignificant per discretion Investigator . No history addiction recreational drug drug dependence . No participation clinical study within past 60 day prior receive first dose investigational product current study . A history allergic adverse reaction Methotrexate Sodium related drug excipient methotrexate tablet . Females childbearing potential unwilling use adequate contraception ( define protocol ) throughout trial one month last dose study medication . Males unwilling use male condom throughout trial three month last dose study medication Patients alcoholism , alcoholic liver disease chronic liver disease . Patients diagnose HIV Hepatitis B ( HBsAg ) Hepatitis C ( HCV ) virus reactive/positive . Patients clinically significant abnormal laboratory value screen . Patients evidence organ dysfunction clinically significant deviation normal physical clinical evaluation include ECG Xray result except study indication . Patients overt laboratory evidence immunodeficiency syndrome . Patients currently suffer history malignant lymphoma tumor lysis syndrome . Patients preexist hematopoietic impairment/ blood dyscrasia , bone marrow hypoplasia , aplastic anemia , pancytopenia , leukopenia , neutropenia , thrombocytopenia significant anemia . Patient lymphadenopathy lymphoproliferative disorder . Patients suffer acute infection within two week prior randomization . Patients clinically significant past history current medical condition : Pulmonary disorder ( Pneumonia , COPD asthma ) , pleural effusion , Cardiovascular disorder ( especially cardiac block , pericarditis , pericardial effusion , hypotension thromboembolic event ) , Neurological disorder ( especially seizures , migraine ) , Gastrointestinal tract disorder include history presence significant gastric and/or duodenal ulceration bleeding , hematemesis , melena , enteritis , pancreatitis , Renal and/or hepatic disorder , Coagulation disorder , Patient ascites , Patient uncontrolled diabetes mellitus . Female patient pregnant breastfeed History presence cancer . Evidence significant uncontrolled concomitant disease investigator 's opinion would exclude patient participation . Expected change concomitant medication period study . Tested positive Alcohol breath Urine drug abuse . Any treatment could affect pharmacokinetic methotrexate ( NSAIDs , salicylates , hypoglycemics , diuretic , sulphonamides , diphenylhydantoin , tetracycline , chloramphenicol paminobenzoic acid , probenecid , penicillin , Chloroquine , omeprazole , etretinate , cotrimoxazole trimethoprim etc . ) administer within 1 month start study . Patient major surgery within 4 week prior study entry , recover prior major surgery . Patients significant history noncompliance medical regimen inability grant reliable informed consent . History difficulty donate blood difficulty accessibility vein . Patients oral administration drug possible . An unusual abnormal diet , whatever reason e.g . religious fast . Blood donation/ loss exceed 200 ml within last 60 day prior receive first dose investigational product current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>